Ceribell, the developer of a diagnostic system powered by artificial intelligence (AI), has hired Louisa Daniels as its general counsel. In her new role, she leads the company’s legal, governance, compliance and ethics functions.
Daniels was previously chief legal officer, general counsel and chief compliance officer for Recursion Pharmaceuticals, which she helped take public in April 2021. Before her tenure at Recursion, she was a vice president and assistant general counsel at Pfizer, where at different times she was chief counsel for global product development, global commercial operations, strategy & portfolio management and pharmatherapeutics research & development.
Earlier in her career she was an in-house attorney at Elan Pharmaceuticals and Tularik.
Ceribell bills itself as the developer of the first AI-powered point-of-care electroencephalogram (EEG) diagnostic system. An EEG is a neurological test that can be used to diagnose seizures related to, for example, brain tumors.
Ceribell co-founder and CEO Jane Chao says in a statement: ‘Louisa Daniels is an accomplished legal strategist and industry leader. [Her] extensive experience will be a tremendous asset for Ceribell as we enter the next phase of rapid growth and work to make point-of-care EEGs available to more providers and their patients.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
